Adeno-associated virus (AAV) producer cell lines represent an effective method for large-scale production of AAV vectors. We set out to evaluate and characterize the use of an abbreviated protocol to generate “masterwells” (MWs; a nonclonal cell population) as a platform for research and preclinical vector production. In this system, a single plasmid containing three components, the vector sequence, the AAV rep, and cap genes, and a selectable marker gene is stably transfected into HeLaS3 cells. Producer cell lines generating an AAV2 vector expressing a secreted form of human placental alkaline phosphatase (SEAP) have been created. Several MWs showed vector yields in the 5×104 to 2×105 DNase-resistant particles/cell range, and the productivity was stable over >60 population doublings. Integrated plasmid copy number in three high-producing MWs ranged from approximately 12 to 50; copies were arranged in a head-to-tail configuration. Upon infection with adenovirus, rep/cap copy number was amplified approximately 100-fold and high yield appeared to be dependent on the extent of amplification. Rep/cap gene expression and vector packaging both reached a peak at 48 hr postinfection. AAV2-SEAP vector was produced in 1-liter shaker culture and purified for assessment of vector quality and potency. The data showed that the majority of the capsids from the MWs contained vector DNA (≥70%) and that purified vector was free of replication-competent AAV. In vitro and in vivo analyses demonstrated that potency of the producer cell-derived vector was comparable to vector generated via the standard transfection method.
Martin and colleagues describe an adeno-associated viral (AAV) vector manufacturing process that uses "master wells," which are nonclonal producer cell populations. The cell lines generated by this process are capable of efficient (>100,000 DNase-resistant particles per cell) and stable (>60 passages) vector production.
Get full access to this article
View all access options for this article.
References
1.
AliR., SarraG.M., StephensC.et al.2000. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet., 25:306–310.
2.
AllayJ.A., SleepS., LongS.et al.2011. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum. Gene Ther., 22:595–604.
3.
AllenJ.M., DebelakD.J., ReynoldsT.C., MillerD.1997. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J. Virol., 71:6816–6822.
4.
AyusoE., MingozziF., BoschF.2010. Production, purification and characterization of adeno-associated vectors. Curr. Gene Ther., 10:423–436.
5.
BainbridgeJ.W., SmithA.J., BarkerS.S.et al.2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med., 358:2231–2239.
6.
BlouinV., BrumentN., ToublancE.et al.2004. Improving rAAV production and purification: towards the definition of a scaleable process. J. Gene Med., 6:S223–S228.
7.
BoccardoE.2010. HPV-mediated genome instability: at the roots of cervical carcinogenesis. Cytogenet. Genome Res., 128:57–65.
CaoM., ZyuH., BandyopadhyayS.et al.2011. HPV-16 E1, E2 and E6 each complement the Ad5 helper gene set, increasing rAAV2 and wt AAV2 production. Gene Ther., 19:418–424.
10.
ChadeufG., FavreD., TessierJ.et al.2000. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus–induced amplification of the integrated rep-cap genome. J. Gene Med., 2:260–268.
11.
ChadeufG., CironC., MoullierP., SalvettiA.2005. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther., 12:744–753.
12.
ChangL.S., ShiY., ShenkT.1989. Adeno-associated virus p5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J. Virol., 8:3479–3488.
13.
ChenT.R.1988. Re-evaluation of HeLa, HeLa S3 and HEp-2 karyotypes. Cytogenet. Cell Genet., 48:19–24.
14.
ChusainowJ., YangY.S., YeoJ.H.M.et al.2009. A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer?Biotechnol. Bioeng., 102:1182–1196.
15.
CideciyanA.V., AlemanT.S., BoyeS.L.et al.2008. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. USA, 105:15112–15117.
16.
CideciyanA.V., HauswirthW.W., AlemanT.S.et al.2009a. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther., 20:999–1004.
17.
CideciyanA.V., HauswirthW.W., AlemanT.S.et al.2009b. Vision 1 year after gene therapy for Leber's congenital amaurosis. N. Engl. J. Med., 361:725–727.
18.
ClarkK.R., VoulgaropoulouF., FraleyD.M., JohnsonP.R.1995. Cell lines for the production of recombinant adeno-associated virus Hum. Gene Ther., 6:1329–1341.
19.
FanP., DongJ.1997. Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV. Hum. Gene Ther., 8:87–98.
FarsonD., HardingT.C., TaoL.et al.2004. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene Med., 6:1369–1381.
22.
GaoG.-P., QuG., FaustL.Z.et al.1998. High-titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum. Gene Ther., 9:2353–2362.
23.
GaoG.-P., LuF., SanmiguelJ.C.et al.2002. Rep/cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol. Ther., 5:644–649.
24.
GaoG.-P., WangQ., WangL.et al.2008. Inadvertent gene transfer of co-packaged rep and cap sequences during the production of AAV vector and its potential impact on vector performance. Mol. Ther., 16:S105–S106.
25.
GrahamF.L., PrevecL.1991. Manipulation of adenovirus vectors. Gene Transfer and Protocol, 7MurrayE.J.Humana Press: Clifton, NJ, 109–128.
26.
GrimmD., KernA., RittnerK., KleinschmidtJ.A.1998. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther., 9:2745–2760.
27.
GrimmD., KernA., PawlitaM.et al.1999. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther., 6:1322–1330.
28.
HauckB., MurphyS.L., SmithP.H.et al.2009. Undetectable transcription of cap in a clinical AAV vector: Implications for preformed capsid in immune responses. Mol. Ther., 17:144–152.
29.
HenckaertsE., DutheilN., ZeltnerN.et al.2009. Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proc. Natl. Acad. Sci. USA, 106:7571–7576.
30.
HerzogR.W., YangE.Y., CoutoL.B.et al.1999. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX by adeno-associated viral vector. Nat. Med., 5:56–63.
31.
HorerM., WegerS., ButzK.et al.1995. Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J. Virol., 69:5485–5496.
32.
HowdenS.E., VoullaireL., VadolasJ.2008. The transient expression of mRNA coding for Rep protein from AAV facilitates targeted plasmid integration. J. Gene Med., 10:42–50.
33.
InoueN., RussellD.W.1998. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J. Virol., 72:7024–7031.
34.
JennyC., ToublancE., DanosO., MertenO.-W.2005. Evaluation of a serum-free medium for the production of rAAV-2 using HeLa derived producer cells. Cytotechnology, 49:11–23.
35.
JiangZ., HuangY., SharfsteinS.T.2006. Regulation of recombinant monoclonal antibody production in Chinese hamster ovary cells: a comparative study of gene copy number, mRNA level, and protein expression. Biotechnol. Prog., 22:313–318.
36.
KaplittM.G., LeoneP., SamulskiR.J.et al.1994. Long-term gene expression and phenotypic correction using adeno-associated virus ectors in the mammalian brain. Nat. Genet., 8:148–154.
37.
KogureK., UrabeM., MizukamiH.et al.2001. Targeted integration of foreign DNA into a defined locus on chromosome 19 in K562 cells using AAV-derived components. Int. J. Hematol., 73:469–475.
LabowM.A., HermonatP.L., BernsK.I.1986. Positive and negative autoregulation of the adeno-associated virus type 2 genome. J. Virol., 60:251–258.
40.
LiJ., SamulskiR.J., XiaoX.1997. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol., 71:5236–5243.
41.
LindenR.M., WinocourE., BernsK.I.1996. The recombination signals for adeno-associated virus site-specific integration. Proc. Natl. Acad. Sci. USA, 93:7966–7972.
42.
LiuX.L., ClarkK.R., JohnsonP.R.1999. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther., 6:293–299.
43.
LiuX.L., VoulgaropoulouF., ChenR.et al.2000. Selective rep-cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther., 2:394–403.
44.
MacvilleM., SchrockE., Padilla-NashH.et al.1999. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res., 59:141–150.
45.
MaguireA.M., SimonelliF., PierceE.A.et al.2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358:2240–2248.
46.
MaguireA.M., HighK.A., AuricchioA.et al.2009. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet, 374:1597–1605.
47.
MathewsL., GrayJ.T., GallagherM.R., SnyderR.O.2002. Recombinant adeno-associated viral vector production using stable packaging and producer cell lines. Meth. Enz., 346:393–413.
48.
McCartyD.M., ChristensenM., MuzyczkaN.1991. Sequences required for coordinate induction of adeno-associated virus p19 and p40 by Rep protein. J. Virol., 65:2936–2945.
49.
MeissnerJ.D.1999. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J. Gen. Virol., 80:1725–1733.
50.
MeyersC., AlamS., ManeM., HermonatP.L.2001. Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue. Virology, 287:30–39.
51.
MouwM.B., PintelD.J.2000. Adeno-associated virus RNA's appear in a temporal order and their splicing is stimulated during coinfection with adenovirus. J. Virol., 74:9878–9888.
52.
MuzyczkaN.1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol., 158:97–129.
53.
NathwaniA.C., TuddenhamE.G., RangarajanS.et al.2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365:2357–2365.
54.
NonyP., TessierJ., ChadeufG.et al.2001. Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J. Virol., 75:9991–9994.
55.
OgstonP., RajK., BeardP.2000. Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein. J. Virol., 8:3494–3504.
56.
PendseT.J., KarkareS., BaileyJ.E.1992. Effect of cloned gene dosage on cell growth and hepatitis B surface antigen synthesis and secretion in recombinant CHO cells. Biotechnol. Bioeng., 40:119–129.
57.
PereiraD.J., McCartyD.M., MuzyczkaN.1997. Adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J. Virol., 71:1079–1088.
58.
PhilpottN., GomosJ., Falck-PedersenE.2004. Transgene expression after Rep-mediated site-specific integration into chromosome19. Hum. Gene Ther., 15:47–61.
59.
PieroniL., FipaldiniC., MonciottiA.et al.1998. Targeted integration of adeno-associated virus-derived plasmids in transfected human cells. Virology, 249:249–259.
60.
PopescuN.C., DiPaoloJ.A., AmsbaughS.C.1987. Integration sites of human papollomavirus 18 DNA sequences on HeLa cell chromosomes. Cytogenet. Cell Genet., 44:58–62.
61.
QiaoC., WangB., ZhuX.et al.2002. A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol., 76:13015–13027.
62.
SimonelliF., MaguireA.M., TestaF.et al.2010. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther., 18:643–650.
63.
SnyderR.O., MiaoC., MeuseL.et al.1999. Correction of hemophila B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med., 5:64–70.
64.
SuroskyR.T., UrabeM., GodwinS.et al.1997. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J. Virol., 71:7951–7959.
65.
TamayoseK., HiraiY., ShimadaT.1996. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum. Gene Ther., 7:507–513.
66.
TatalickL.M., GerardC.J., TakeyaR.et al.2005. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. Vaccine, 23:2628–2638.
67.
TessierJ., ChadeufG., NonyP.et al.2001. Characterization of adenovirus-induced inverted terminal repeat-independent amplification of integrated adeno-associated virus rep-cap sequences. J. Virol., 75:375–383.
ToublancE., BenraissA., BonninD.et al.2004. Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J. Gene Med., 6:555–564.
70.
TsunodaH., HayakawaT., SakuragawaN., KoyamaH.2000. Site-specific integration of adeno-associated virus-based plasmid vectors in lipofected HeLa cells. Virology, 68:391–401.
71.
VincentK.A., PirainoS.T., WadsworthS.C.1997. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J. Virol., 71:1897–1905.
72.
WangX.S., KhuntiratB., QingK.et al.1998. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J. Virol., 2:5472–5480.
73.
WardP., EliasP., LindenR.M.2003. Rescue of the adeno-associated virus genome from a plasmid vector: evidence for rescue by replication. J. Virol., 77:11480–11490.
74.
WegerS., WistubaA., GrimmD., KleinschmidtJ.A.1997. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and rep proteins. J. Virol., 71:8437–8447.
75.
WistubaA., WegerS., KernA., KleinschmidtJ.A.1995. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol., 9:5311–5319.
YangQ., ChenF., TrempeJ.P.1994. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J. Virol., 8:4847–4856.
78.
YewN., PrzybylskaM., ZieglerR.J.et al.2001. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol. Ther., 4:75–82.
79.
Yla-HerttualaS.2012. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther., 20:1831–1832.
80.
YouH., LiuY., PrasadC.K.et al.2006. Multiple human papillomavirus genes affect the adeno-associated virus life cycle. Virology, 2:532–540.
81.
YuanZ., QiaoC., HuP.et al.2011. A versatile AAV producer cell line method for scalable vector production of different serotypes. Hum. Gene Ther., 22:613–624.
82.
ZeltnerN., KohlbrennerE., ClementN.et al.2010. Near perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther., 17:872–879.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
